PharmAust share price soars on release of results
Shares in PharmAust Ltd (ASX:PAA) opened at 15 cents on Thursday morning, representing a gain of nearly 40% on the previous day’s close in response to extremely positive news regarding the performance of its treatments in reducing SARS-CoV-2 (COVID-19) cell-to-cell infectivity in cell culture in a repeat preliminary experimental evaluation.
The clinical stage oncology group provided an update on its repeat cell culture preliminary experiments investigating the effects of monepantel (MPL) and monepantel sulfone (MPLS) upon cells infected with SARS-CoV-2 in cell culture.
PharmAust’s lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway, a key driver of cancer.
MPL has been evaluated in Phase I clinical trials in humans and dogs, and it was well tolerated and produced a significant reduction in key prognostic biomarkers.
The company is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase II clinical trials.
Today’s news focused on the replication of the in vitro virus infectivity experiment and using the same TCID50 method as that announced a fortnight ago, it confirmed initial findings.
qPCR is quicker, cheaper and less labour intensive, yet a less informative experiment than TCID50.
It is initially used to check whether TCID50 should be performed.
Given both qPCR and TCID50 both showed monepantel antiviral activity in the previous experimental set, only TCID50 was performed in the repeat experiment which demonstrated that infectivity of SARS-CoV2 virus particles can be suppressed by up to approximately 95% in cell cultures by either MPL or MPLS.
High profile collaborative pre-clinical experimentation imminent
PharmAust is now engaged in further discussions with the Walter and Eliza Hall Institute to investigate key next steps to further explore the significance of this work.
Importantly, this will include comparisons with other mTOR inhibitors, such as rapamycin and current anti-viral drugs authorised by the FDA for emergency use to treat COVID-19, such as remdesivir.
By way of background, Walter and Eliza Hall Institute researcher Professor Marc Pellegrini (MBBS BSc FRACP PhD FAHMS) is joint head of the Institute’s Infectious Diseases and Immune Defence division and an infectious disease clinician at the Royal Melbourne Hospital.
Highlighting the significance of these findings, Pellegrini said, “These are encouraging anti-viral profiles.
‘’These exciting repeat results validate the results of the initial test and form strong grounds for progressing the drug to the next step.
‘’Demonstrating twice that infectivity of SARS-CoV-2 virus particles can be suppressed by up to approximately 95% in cell cultures is a remarkable outcome.
‘’We intend to continue collaborating with PharmAust with pre-clinical experimentation to support their progress.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.